Skip to main content
OpenTrials
Completed

NCT Number: NCT02721017

Cryoanalgesia vs. Epidural in the Nuss Procedure

The purpose of this study is to determine whether cryoanalgesia provides better pain control for minimally invasive pectus excavatum repair (the Nuss procedure) than thoracic epidural.

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

UCSF-Benioff Children's Hospital

San Francisco, California, 94158, United States

About this study

Pain control is a major challenge for physicians, who must ensure appropriate and effective pain control for their patients, while remaining mindful of the many negative effects of opioid dependence and addiction. Nowhere is there a more pressing need than in children and young adults, who are at high risk for drug abuse, and in post-operative care, since post-operative opioid use can be a starting point for long-term pain issues. Postoperative pain control in the Nuss procedure, minimally invasive repair of the congenital chest wall deformity known as pectus excavatum, remains a significant problem for the 3000 patients who undergo this procedure each year, mostly adolescents and young adults. Many multimodal analgesic regimens have been tried, but optimal treatment remains unknown.

This study will test a novel and promising strategy of using intra-operative cryoanalgesia during the Nuss procedure. Cryoanalgesia is the localized, temporary freezing of peripheral nerves, which is performed at the time of the Nuss procedure. The study is a 20-subject prospective, randomized pilot trial comparing cryoanalgesia to thoracic epidural analgesia for post-operative pain control in patients undergoing the Nuss procedure. Subjects will be recruited from patients already scheduled for a Nuss procedure at our institution, and will undergo 1:1 randomization to either cryoanalgesia or thoracic epidural analgesia for perioperative pain control. During their hospitalization, patients' opiate usage will be prospectively recorded, and pain will be assessed twice per day. Upon discharge, patients will maintain a log of their opiate use, and will return to clinic at 2 weeks, 1 month, 3 months, and 1 year after Nuss procedure for post-operative assessment. Primary outcome is length of perioperative hospitalization, an objective measure that synthesizes many different aspects of a procedure and its subsequent post-operative course, including pain control. Secondary outcomes are post-operative narcotic usage and direct cost of perioperative hospitalization. Side effects of both interventions will also be assessed.

This will be the first systematic investigation of cryoanalgesia for local nerve block in a thoracoscopic procedure, and the first study involving its use in adolescents and young adults. The results will have direct application for those undergoing the Nuss procedure to repair pectus excavatum. Investigators will also delineate a reproducible protocol for delivering cryoanalgesia thoracoscopically, to ensure others can safely and effectively use this method if it proves beneficial. Although the focus is on the small subset of patients who undergo the Nuss procedure, if a standardized approach to cryoanalgesia delivery in a thoracoscopic procedure has a positive effect on patient outcomes and cost of hospitalization, the technique could be applied to a variety of surgical procedures, as well as for other neuropathic pain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • scheduled for Nuss procedure for pectus excavatum correction
  • at least 13 years old at the time of the procedure

Exclusion criteria

  • age less than 13 years at time of procedure
  • use of pain medication prior to procedure
  • pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum
  • previous repair of pectus excavatum by any technique
  • previous thoracic surgery
  • congenital heart disease
  • bleeding dyscrasia
  • major anesthetic risk factors or history of previous problem with anesthesia
  • pregnancy
  • inability to communicate in English

Treatment and study plan

Cryoanalgesia

Device

Other names: AtriCure, cryoprobe, nerve freezing

Thoracic epidural (ropivicaine, fentanyl)

Drug

Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.

Other names: Epidural

Primary outcomes

  1. Length of Hospitalization

    Time frame: estimated one week or less

    the length of the patient's in-hospital stay following admission for Nuss procedure

Secondary outcomes

  1. Narcotic Usage

    Time frame: Post Operative Hospital Stay

    Inpatient narcotic usage

  2. Mean Neuropathic Pain Score at One Year

    Time frame: one year

    Neuropathic specific pain (described as "burning", "electrical" or "tingling" sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).

  3. Cost Analysis

    Time frame: estimated one week

    cost analysis of initial hospitalization following Nuss procedure

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Food and Drug Administration (FDA)

Registry information

Official study title

Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Mar 28, 2016
Registry last updated
May 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.